Cardior Pharmaceuticals GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.cardior.de
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Phase 2
Withdrawn
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Registration Number
- NCT05953831
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
Phase 2
Completed
- Conditions
- Myocardial Infarction, AcuteHeart Failure, Left Sided
- Interventions
- Drug: Placebo to CDR132L
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 294
- Registration Number
- NCT05350969
- Locations
- 🇵🇱
Polsko Amerykanskie Kliniki Serca, Kędzierzyn-Koźle, Poland
🇵🇱NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog, Sopot, Poland
🇳🇱Deventer Ziekenhuis, Deventer, Netherlands
Clinical Study to Assess Safety, PK and PD Parameters of CDR132L
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Cardior Pharmaceuticals GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT04045405
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath